🇺🇸

US SEC Filing Intelligence

· daily

All NASA Contracts — September 12, 2026

This digest covers $339.7M in NASA contracts from September 2026, with one defense-related award (the Artemis/ULA contract) and one civilian IT services contract. The dominant theme is NASA’s deep-space exploration push under Artemis, anchored by a $59.5M sole-source award to United Launch Services for Centaur upper stages. The highest-conviction signal is the stable, long-term revenue visibility for ULA’s parent from the $177.4M total potential contract through 2031, though the fixed-price structure introduces execution risk. A key risk is the expired $280.2M ASRC IT contract, which signals potential revenue decay for Arctic Slope Regional Corporation unless new NASA awards materialize. Overall, the digest highlights a bifurcated NASA spending profile: high-priority exploration (Artemis) versus legacy IT services.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — September 11, 2026

This digest covers a single, large civilian infrastructure contract totaling $173.7 million awarded to Whiting-Turner Contracting Company by the U.S. Coast Guard (Department of Homeland Security) for the Base Seattle CERCLA/PSC Homeport Phase 1B construction project. The contract is fully civilian, with no defense-related awards in this period. The dominant theme is continued investment in federal facility construction, particularly environmental remediation and homeport upgrades. The highest-conviction signal is neutral, given the firm-fixed-price structure and full competition, which offers predictable revenue but carries execution risk over the 2.8-year performance period. Key risks include high pricing risk under the fixed-price model and potential environmental or permitting delays at the Seattle site.

1 total filings
· daily

DHS Homeland Security Contracts — September 11, 2026

A single $173.7 million firm-fixed-price delivery order from the U.S. Coast Guard (DHS) to Whiting-Turner Contracting Company dominates this period, representing 100% of the aggregate obligation. This is a civilian infrastructure contract with no defense exposure, signaling stable but non-cyclical DHS facilities spending. The neutral signal (5/10) reflects a competitive win with no set-aside, but high execution risk due to the fixed-price structure and nearly three-year performance window. Key risk: potential cost overruns on the Seattle CERCLA/PSC Homeport project given environmental remediation complexity.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — September 11, 2026

This digest covers a single $68.2 million cost-plus-fixed-fee contract awarded to Philips North America LLC by BARDA (within HHS) for developing a detection system for burns, traumatic injuries, and COVID-19 viral pneumonia. The contract is defense-related, reflecting biodefense priorities, and spans May 2020 through December 2026, with 74% already outlayed, indicating steady performance and cash flow. The neutral signal strength (5/10) and low materiality (4/10) suggest limited near-term investment impact, but the contract's extension through 2026 provides revenue visibility. Key risks include BARDA budget volatility and pandemic-era funding normalization, while the cost-plus structure offers predictable margins for Philips.

1 total filings
· daily

New Federal Contractors — September 11, 2026

Six contracts totaling $1.18 billion were analyzed, with a 2:4 defense-to-civilian split, dominated by the Department of Health and Human Services (HHS/CDC/BARDA) at $733M combined, signaling robust civilian biodefense and IT infrastructure spending. The highest-conviction signal is SANOFI's subsidiary PROTEIN SCIENCES CORP's $146.7M cost-plus-fixed-fee BARDA contract, a low-risk, high-visibility biodefense R&D award. The primary risk is the lack of public parent company data for I3 FEDERAL LLC ($518M CDC contract), creating opacity around execution capacity for a small business handling a very large fixed-price IT contract. A key watch item is the potential follow-on to the 2027-expiring SPATIAL FRONT INC Census Bureau BPA.

6 total filings
· daily

Significant Contract Modifications ($10M+) — September 11, 2026

Over the September 11, 2026 to September 11, 2026 period, 7 significant contract modifications totaling $1.18B were recorded, with only 2 being Defense-related ($174.1M combined), dominated by a civilian-heavy profile led by the Department of Health and Human Services at $732.9M (62% of total). The highest-conviction signal is Protein Sciences Corp's $146.7M BARDA contract for biodefense R&D, offering a bullish low-risk CPFF structure, though the contract is mature and options remain unconfirmed. A key risk is the heavy reliance on I3 Federal LLC ($518M, HHS CDC), a small SDVOSB firm-facing fixed-price execution risk and scalability constraints on the DCIPHER Ecosystem IT contract, with no public parent company to absorb potential overruns.

7 total filings
· daily

Contract Deobligations Alert — September 11, 2026

The 7 contracts in this digest total $1.18 billion in obligations, with only 2 of 7 being defense-related (DHS/Coast Guard) and 5 civilian (HHS, NRC, Commerce). The dominant theme is civilian agency IT modernization and biodefense, led by a $518M CDC IT contract to I3 Federal LLC and a $208M NTT DATA services contract with the NRC. The highest-conviction signal is the $146.7M BARDA biodefense R&D contract to Protein Sciences Corp (Sanofi subsidiary), as its cost-plus-fixed-fee structure and small business classification despite Sanofi parentage signal attractive government risk-sharing. Key risk: fixed-price execution on the $518M I3 Federal CDC contract by an SDVOSB with unknown parent backing could pose delivery or margin challenges.

7 total filings
· daily

Biotech Small-Cap Approvals — September 11, 2026

This digest covers two biosimilar approvals from September 2026: BRIVARACETAM (Zhejiang Jutai Pharm) and TOPIRAMATE (Micro Labs). Neither is a new molecular entity (NME), biosimilar, or label expansion, resulting in a neutral investment signal for both. The approvals fall under the 'Other' category, suggesting they may be generic or additional filings with limited commercial differentiation. No dominant therapeutic area theme or high-conviction signal emerges, as both drugs target established market segments with known competitive dynamics. The key risk is the lack of material exclusivity or pricing power due to their non-NME status.

2 total filings
· daily

Big Pharma Approvals — September 11, 2026

The FDA approval landscape for September 11, 2026, features a single NME approval: AstraZeneca's CAMIZESTRANT (branded ETCAMAH), a strong bullish signal for the sponsor. With no biosimilars or label expansions in this period, the focus narrows to a major new molecular entity launch. This single event underscores AstraZeneca's continued pipeline execution in a key therapeutic area. The primary risk is the lack of disclosed commercial specifics (peak sales, pricing, market position), requiring close monitoring of launch dynamics.

1 total filings
· daily

New Drug Approvals (Original) — September 11, 2026

During this period, the FDA approved three drugs: two biosimilars (BRIVARACETAM from ZHEJIANG JUTAI PHARM and TOPIRAMATE from MICRO LABS) and one NME (CAMIZESTRANT from ASTRAZENECA PHARMACEUTICALS, LP). The dominant therapeutic area theme is CNS, with both biosimilar approvals targeting antiseizure markets and the NME in an undisclosed but likely oncology or CNS-related indication. The highest-conviction signal is the approval of CAMIZESTRANT by ASTRAZENECA, as it represents a new molecular entity and a strong bullish signal, albeit with undisclosed peak sales and exclusivity. Key risks include the lack of commercial details for all three drugs and the competitive pressure from biosimilar entrants to their respective originators.

3 total filings
· daily

Contract Option Exercises — September 11, 2026

The seven contract option exercises total $1.18 billion, with a heavy civilian tilt (5 of 7 contracts, 86% of aggregate value) led by the Department of Health and Human Services ($732.9M combined from CDC and BARDA awards). The highest-conviction signal is Sanofi subsidiary Protein Sciences Corp's $146.7M BARDA cost-plus-fixed-fee contract, which offers low execution risk and immediate cash flow from a fully obligated biodefense R&D award. However, the digest's average signal strength of 5.0/10 reflects significant data gaps—including unknown competition signals on six contracts—and the presence of a $406K Lockheed Martin award that is immaterial to the company. Key risk: I3 Federal's $518M fixed-price CDC contract carries medium execution risk for a small business, and the lack of public parent company data limits transparency for investors tracking that revenue stream.

7 total filings
· daily

Federal IT & Cybersecurity Contracts — September 11, 2026

The three contracts analyzed total $791,281,982 in obligations, all from civilian agencies (0/3 defense-related), with the Department of Health and Human Services (CDC) representing the largest award at $517,998,604 to I3 Federal LLC. The dominant theme is civilian IT modernization and support services, particularly in health and census data infrastructure. The highest-conviction signal is the bullish outlook for SPATIAL FRONT INC's $65.1M Census Bureau contract, given strong performance and 8(a) advantages. Key risks include execution risk on fixed-price contracts, revenue concentration for small businesses, and the lack of public financial data for I3 Federal and SPATIAL FRONT, limiting investment clarity.

3 total filings
· daily

All HHS Contracts — September 11, 2026

This digest covers three HHS contracts totaling $732.9M in obligations, with two of the three (BARDA awards to Protein Sciences/Sanofi and Philips North America) carrying defense-related biodefense implications. The dominant theme is HHS investment in IT modernization and biodefense R&D, led by a $518M CDC IT contract to I3 Federal LLC. The highest-conviction signal is the $146.7M obligated BARDA contract to Sanofi's Protein Sciences Corp, which is cost-plus-fixed-fee and fully funded, reducing execution risk. Key risks include I3 Federal's fixed-price execution risk as an SDVOSB on a large IT contract and BARDA budget normalization post-pandemic, which could affect follow-on funding.

3 total filings
· daily

Mega Contracts Monitor ($100M+) — September 11, 2026

This digest covers $1.05B in contract obligations from four awards, with only one defense-related contract (25%) and the remainder civilian, primarily from HHS/CDC and BARDA. The dominant sector theme is civilian agency IT modernization and biodefense R&D, with the $518M I3 Federal CDC DCIPHER contract representing the highest-conviction revenue signal—though execution risk is elevated due to fixed-price structure and small business capacity constraints. The lone defense contract, Whiting-Turner’s $174M Coast Guard construction award, signals ongoing facilities investment but carries high fixed-price execution risk over nearly three years. A key risk: the Sanofi/Protein Sciences $147M BARDA contract (2009-2016) is historic data with uncertain follow-on, while NTT Data’s $208M NRC contract from 2014 lacks performance detail, limiting forward-looking clarity.

4 total filings
· daily

High-Value Federal Grants ($5M+) — September 11, 2026

The six contracts analyzed total $1.18 billion in obligations, with a 2/6 defense-related split (33% by count, but only the DHS Coast Guard contract is clearly defense-aligned; the NRC contract is civilian). The dominant theme is civilian agency IT and R&D spending, led by HHS (CDC and BARDA) at $732.9M combined, or 62% of total value. The highest-conviction signal is the $518M CDC DCIPHER award to I3 Federal LLC, a small SDVOSB, which provides stable revenue through 2027 but carries fixed-price execution risk. A key risk is the $208M NTT DATA NRC contract from 2014 with no performance data, which adds opacity to the digest's overall reliability. The digest shows no bearish signals, but the neutral-to-bullish tilt is tempered by medium-to-high pricing risk on two large fixed-price awards (I3 Federal and Whiting-Turner).

6 total filings
· daily

General Federal Contracts — September 11, 2026

The six contracts analyzed total $1.18 billion in obligations, with a civilian-heavy split (4 of 6 contracts, $798M) led by the Department of Health and Human Services (HHS) at $733M, including a $518M CDC IT contract to I3 Federal LLC and a $147M BARDA biodefense R&D contract to Sanofi subsidiary Protein Sciences Corp. Defense-related contracts ($382M) are limited to a $174M Coast Guard construction award to Whiting-Turner Contracting Company and a $208M NRC IT services contract to NTT Data Services Federal Government, though the latter is civilian. The highest-conviction signal is bullish for Protein Sciences Corp ($147M obligated, $508M potential) due to its cost-plus-fixed-fee structure and critical biodefense mission, while the key risk is execution on I3 Federal's $518M fixed-price CDC contract given its small business designation and capacity constraints.

6 total filings
· daily

S&P 500 Technology Sector SEC Filings — September 11, 2026

The 14 filings predominantly consist of routine insider grants and sales, with one major quarterly earnings report from Oracle that dominates the portfolio picture. Oracle's Q1 FY2027 results reveal a powerful transition, with Cloud revenues surging 61.5% YoY and driving a 29.6% total revenue increase, though this is accompanied by significant cash burn from $28.5B in capital expenditures and a reliance on customer prepayments for cash flow. The insider activity is largely neutral compensation grants (Microsoft directors) and pre-planned sales (Qualcomm CFO, CrowdStrike CEO), offering no strong conviction signals. The lack of filings from other major S&P 500 Tech constituents limits broad sector synthesis, making Oracle's singular performance and capital allocation approach the central investment theme to analyze. Period-over-period data from Oracle shows expanding operating margins (+610 bps YoY), contrasting with rising interest expenses (+54.7% YoY), highlighting a tale of growth leverage versus financial leverage. The portfolio-level pattern is one of data scarcity, directing focus squarely on Oracle's cloud-driven transformation and its sustainability.

4 high priority 10 medium 14 total filings
· daily

Nasdaq 100 Stocks SEC Filings — September 11, 2026

The 19 filings, all Form 4 insider transactions from NASDAQ-100 constituents, reveal a day of routine equity compensation activity punctuated by notable insider selling. Microsoft directors received routine RSU awards, reflecting standard governance, while Gilead executives exercised and withheld shares for taxes, a typical non-discretionary event. The most significant signals are the Rule 10b5-1 plan sales by Meta's Chief Product Officer ($13M) and Qualcomm's CFO ($136K), which, while pre-scheduled, occur at elevated valuations and warrant monitoring. No forward-looking guidance, capital allocation changes, or M&A activity were disclosed in these filings. The absence of open-market buying and the presence of planned selling at major tech names suggests a cautious insider stance, though the sales are not alarming given their planned nature. Overall, the data points to a neutral-to-slightly-bearish insider sentiment, with no acute red flags but also no strong conviction buying.

9 high priority 10 medium 19 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — September 11, 2026

This batch of 36 filings reveals a surge in activist and insider activity, with several campaigns targeting governance and strategic changes at small- to mid-cap companies. Notable activist pushes include a special tender offer for Evogene Ltd., a public campaign at Freightos, and a call for a full sale at TransAct Technologies. Insider selling is pronounced, with Andreessen Horowitz reducing its Nautilus Biotechnology stake below 5%, Squadron Capital trimming its OrthoPediatrics position, and the Toro 18 group selling Universal Electronics shares. Conversely, Fairmount Funds has taken a 19.99% stake in Korsana Biosciences, and Conversant Capital acquired a 9.8% stake in Vulcan Infrastructure. The Rent the Runway filings highlight a coordinated capital raise with a $15M rights offering backstopped by major holders, while the American Homes 4 Rent filings show a significant ownership restructuring as the B. Wayne Hughes estate distributes shares. Overall, the period is marked by high-conviction activist entries, partial exits by early investors, and several companies undergoing capital structure changes, creating a rich environment for event-driven strategies.

25 high priority 11 medium 36 total filings
· daily

S&P 500 Energy Sector SEC Filings — September 11, 2026

Today's session was exceptionally quiet for the S&P 500 Energy sector, with only one filing from Texas Pacific Land Corp (TPL) containing enriched data. The filing reveals a minimal insider purchase by a 10% owner, Horizon Kinetics Asset Management LLC, of a single share at $366.18. While the transaction is immaterial in size, it occurs against a backdrop of TPL's unique business model as a landowner in the Permian Basin, which benefits from ongoing energy production activity. The lack of other filings across the 20-company universe suggests a period of relative calm, with no major operational updates, capital allocation changes, or guidance revisions from other major integrated oil and gas, exploration and production, or energy services firms. The key takeaway is the absence of sector-wide news, which may indicate a period of stability or consolidation, but also limits the generation of broad, actionable signals from this specific data set.

1 high priority 1 total filings